Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexxar in relapsed/refractory Hodgkin's lymphoma
NCT00484874Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2007
- Primary completion
- Jan 2014
- Countries
- 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Drugs
- tositumomab
- Conditions
- Hodgkin lymphoma (HL)
01
Overview
Phase 2, open-label, single-arm trial of tositumomab in Hodgkin lymphoma (HL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 2 years, Overall Response Rate at 12 weeks and 1 more. Started Jun 2007; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Bexxar Arm
Patients receive a single therapeutic regimen of I-131 Tositumomab.
03
Who it enrols
Adult patients with biopsy-proven relapsed or refractory Hodgkin's lymphoma who have previously undergone transplant or are ineligible for transplant, with adequate organ function and less than 25% bone marrow involvement.
04
Endpoints
Primary
Maximum Tolerated Dose
Overall Response Rate
Complete Response Rate
Secondary
Time to Progression
Frequency of Visualization of Hodgkin's Lymphoma
Tumor Radiation Absorbed Dose
Beyond the preview
Go deeper on NCT00484874.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484874.